Veru Inc. (NASDAQ:VERU) Stock Position Raised by Bank of America Corp DE

Bank of America Corp DE raised its position in shares of Veru Inc. (NASDAQ:VERU) by 17.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,792 shares of the company’s stock after purchasing an additional 32,447 shares during the period. Bank of America Corp DE owned 0.15% of Veru worth $142,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VERU. Oppenheimer & Co. Inc. increased its holdings in shares of Veru by 181.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 1,120,586 shares of the company’s stock valued at $729,000 after acquiring an additional 722,644 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Veru by 37.1% during the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock valued at $49,000 after acquiring an additional 20,430 shares during the period. Barclays PLC lifted its holdings in shares of Veru by 11.8% during the fourth quarter. Barclays PLC now owns 206,515 shares of the company’s stock valued at $134,000 after acquiring an additional 21,738 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Veru by 2,500.0% in the fourth quarter. NewEdge Advisors LLC now owns 130,000 shares of the company’s stock valued at $85,000 after buying an additional 125,000 shares during the last quarter. Finally, Atria Investments Inc raised its holdings in shares of Veru by 21.2% in the fourth quarter. Atria Investments Inc now owns 171,707 shares of the company’s stock valued at $112,000 after buying an additional 30,043 shares during the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Trading Down 1.8%

Shares of NASDAQ:VERU opened at $0.60 on Tuesday. The stock has a market capitalization of $87.92 million, a P/E ratio of -2.31 and a beta of -0.80. Veru Inc. has a 1-year low of $0.45 and a 1-year high of $1.42. The business has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.61.

Veru (NASDAQ:VERU) last posted its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, equities analysts predict that Veru Inc. will post -0.22 EPS for the current year.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.